Cell line modeling for systems medicine in cancers (Review)

Kim,Nayoung; He,Ningning; Yoon,Sukjoon

doi:10.3892/ijo.2013.2202

Cell line modeling for systems medicine in cancers (Review)

Authors:
- Nayoung Kim
- Ningning He
- Sukjoon Yoon
View Affiliations

Affiliations: Center for Advanced Bioinformatics and Systems Medicine, Department of Biological Sciences, Sookmyung Women's University, Seoul 140-742, Republic of Korea
Published online on: December 2, 2013 https://doi.org/10.3892/ijo.2013.2202
Pages: 371-376
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Unexpected drug efficacy or resistance is poorly understood in cancers because of the lack of systematic analyses of drug response profiles in cancer tissues of various genotypic backgrounds. The recent development of high‑throughput technologies has allowed massive screening of chemicals and drugs against panels of heterogeneous cancer cell lines. In parallel, multi‑level omics datasets, including genome‑wide genetic alterations, gene expression and protein regulation, have been generated from diverse sets of cancer cell lines, thus providing a surrogate system, known as cancer cell line modeling, that can represent cancer diversity. Taken together, recent efforts with cancer cell line modeling have enabled a systematic understanding of the causal factors of varied drug responses in cancers. These large-scale association studies could potentially predict and optimize target windows for drug treatment in cancer patients. The present review provides an overview of the major types of cell line‑based large datasets and their applications in cancer studies. Moreover, this review discusses recent integrated approaches that use multi-level datasets to discover synergistic drug combination or repositioning for cancer treatment.

View Figures

View References

1.	Kim N, He N, Kim C, et al: Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer. 131:2456–2464. 2012. View Article : Google Scholar : PubMed/NCBI
2.	Bussey KJ, Chin K, Lababidi S, et al: Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther. 5:853–867. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
4.	Park ES, Rabinovsky R, Carey M, et al: Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 9:257–267. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Lamb J: The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer. 7:54–60. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Shoemaker RH, Monks A, Alley MC, et al: Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res. 276:265–286. 1988.PubMed/NCBI
7.	Greshock J, Bachman KE, Degenhardt YY, et al: Molecular target class is predictive of in vitro response profile. Cancer Res. 70:3677–3686. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Bignell GR, Huang J, Greshock J, et al: High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res. 14:287–295. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Zhao X, Weir BA, LaFramboise T, et al: Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65:5561–5570. 2005. View Article : Google Scholar
10.	Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39:D945–D950. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Weir BA, Woo MS, Getz G, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature. 450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 446:758–764. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Garraway LA, Widlund HR, Rubin MA, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436:117–122. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Savas S, Briollais L, Ibrahim-zada I, et al: A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca²⁺ signaling in selenium resistance. PLoS One. 5:e126012010. View Article : Google Scholar : PubMed/NCBI
15.	Rantala JK, Edgren H, Lehtinen L, et al: Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2. Neoplasia. 12:877–888. 2010.PubMed/NCBI
16.	Cheung HW, Cowley GS, Weir BA, et al: Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA. 108:12372–12377. 2011. View Article : Google Scholar
17.	Abaan OD, Polley EC, Davis SR, et al: The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73:4372–4382. 2013.PubMed/NCBI
18.	Scherf U, Ross DT, Waltham M, et al: A gene expression database for the molecular pharmacology of cancer. Nat Genet. 24:236–244. 2000. View Article : Google Scholar : PubMed/NCBI
19.	Ross DT, Scherf U, Eisen MB, et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 24:227–235. 2000. View Article : Google Scholar : PubMed/NCBI
20.	Dan S, Tsunoda T, Kitahara O, et al: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62:1139–1147. 2002.PubMed/NCBI
21.	Spurrier B, Ramalingam S and Nishizuka S: Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc. 3:1796–1808. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Zubrod CG: Origins and development of chemotherapy research at the National Cancer Institute. Cancer Treat Rep. 68:9–19. 1984.PubMed/NCBI
23.	Paull KD, Shoemaker RH, Hodes L, et al: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 81:1088–1092. 1989. View Article : Google Scholar : PubMed/NCBI
24.	Deeken JF, Robey RW, Shukla S, et al: Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen. Mol Pharmacol. 76:946–956. 2009. View Article : Google Scholar : PubMed/NCBI
25.	McDermott U, Sharma SV, Dowell L, et al: Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA. 104:19936–19941. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Karaman MW, Herrgard S, Treiber DK, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Garnett MJ, Edelman EJ, Heidorn SJ, et al: Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483:570–575. 2012. View Article : Google Scholar : PubMed/NCBI
28.	He N, Wang X, Kim N, Lim JS and Yoon S: 3D shape-based analysis of cell line-specific compound response in cancers. J Mol Graph Model. 43:41–46. 2013. View Article : Google Scholar : PubMed/NCBI
29.	Ma Q and Lu AY: Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 63:437–459. 2011. View Article : Google Scholar : PubMed/NCBI
30.	Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
31.	Zeeberg BR, Kohn KW, Kahn A, et al: Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples. PLoS One. 7:e400622012. View Article : Google Scholar : PubMed/NCBI
32.	Prahallad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Corcoran RB, Cheng KA, Hata AN, et al: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 23:121–128. 2013. View Article : Google Scholar : PubMed/NCBI
34.	Lu Y, Muller M, Smith D, et al: Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene. 30:4567–4577. 2011. View Article : Google Scholar : PubMed/NCBI